康希诺24价肺炎球菌多糖结合疫苗（CRM197/破伤风类毒素）临床试验获批

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24) [1][2] Group 1 - The clinical trial approval indicates that PCV24 meets the requirements for drug registration and is set to prevent infections caused by 24 serotypes of pneumococcus [1] - As of the announcement date, there are no marketed products for the 24-valent pneumococcal polysaccharide conjugate vaccine in both domestic and international markets [2]